A pilot open label prospective study of memantine monotherapy in adults with ADHD

World Journal of Biological Psychiatry

Volumn 14, Issue 4, 2013, Pages 291-298

  Surman, Craig B H ^a,b   Hammerness, Paul G ^a,b   Petty, Carter ^a   Spencer, Thomas ^a,b   Doyle, Robert ^a,b   Napolean, Siena ^a   Chu, Nicole ^a   Yorks, Dayna ^a   Biederman, Joseph ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

ADHD; Adults; Cognition; Memantine; Psychopharmacology

Indexed keywords

MEMANTINE;

ALLERGY; ANOREXIA; ANXIETY; ARTICLE; ASTHMA; ATTENTION; ATTENTION DEFICIT DISORDER; AUDITORY DISCRIMINATION; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; COLD; CONCENTRATION LOSS; DIZZINESS; DRUG DOSE TITRATION; DRUG WITHDRAWAL; ENERGY; EXECUTIVE FUNCTION; FEMALE; GASTROINTESTINAL DISEASE; HEADACHE; HEART PALPITATION; HUMAN; INFECTION; INJURY; INSOMNIA; MALE; MONOTHERAPY; MUSCULOSKELETAL DISEASE; NERVOUSNESS; NEUROPSYCHOLOGICAL TEST; PILOT STUDY; PROSPECTIVE STUDY; REACTION TIME; SEDATION; SEXUAL FUNCTION; SIDE EFFECT; STRUCTURED INTERVIEW; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL DISORDER; WORKING MEMORY; XEROSTOMIA;

ADOLESCENT; ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HUMANS; MALE; MEMANTINE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; RECEPTORS, N-METHYL-D-ASPARTATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84877587284     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.3109/15622975.2011.623716     Document Type: Article

References (40)

1. Arnsten AF. 2006. Stimulants: Therapeutic actions in ADHD. Neuropsychopharmacology 31:2376-2383. (Pubitemid 44607054)
2. Biederman J, Spencer T. 1999. Attention-defi cit/hyperactivity disorder (ADHD) as a noradrenergic disorder. Biol Psychiatry 46: 1234-1242. (Pubitemid 30114440)
3. Biederman J, Faraone SV, Spencer T, Wilens T, Mick E, Lapey KA. 1994. Gender differences in a sample of adults with attention defi cit hyperactivity disorder. Psychiatry Res 53:13-29. (Pubitemid 24266118)
4. Biederman J, Faraone SV, Spencer T, Mick E, Monuteaux M, Aleardi M. 2006a. Functional impairments in adults with selfreports of diagnosed ADHD: A controlled study of 1001 adults in the community. J Clin Psychiatry 67:524-540. (Pubitemid 43764229)
5. Biederman J, Petty C, Fried R, Fontanella J, Doyle AE, Seidman LJ, et al. 2006b. Impact of psychometrically defi ned defi cits of executive functioning in adults with attention defi cit hyperactivity disorder. Am J Psychiatry 163: 1730-1738. (Pubitemid 44522481)
6. Biederman J, Petty CR, Fried R, Doyle AE, Spencer T, Seidman LJ, et al. 2007. Stability of executive function defi cits into young adult years: a prospective longitudinal follow-up study of grown up males with ADHD. Acta Psychiatr Scand 116: 129-136. (Pubitemid 47076271)
7. Biederman J, Petty CR, Fried R, Black S, Faneuil A, Doyle AE, et al. 2008a. Discordance between psychometric testing and questionnaire-based defi nitions of executive function defi cits in individuals with ADHD. J Atten Disord 12:92-102.
8. Biederman J, Seidman LJ, Petty CR, Fried R, Doyle AE, Cohen DR, et al. 2008b. Effects of stimulant medication on neuropsychological functioning in young adults with attention-defi cit/hyperactivity disorder. J Clin Psychiatry 69:1150-1156. (Pubitemid 352031599)
9. Breier A, Adler CM, Weisenfeld N, Su TP, Elman I, Picken L, et al. 1998. Effects of NMDA antagonism on striatal dopamine release in healthy subjects: application of a novel PET approach. Synapse 29:142-147. (Pubitemid 28221792)
10. Bush G, Shin LM, Holmes J, Rosen BR and Vogt BA. 2003. The Multi-Source Interference Task: validation study with fMRI in individual subjects. Mol Psychiatry 8:60-70. (Pubitemid 36188574)
11. Cambridge Cognition Limited. 2004. CANTABeclipse Test Administration Guide.
12. Cochrane A, Barnes-Holmes D, Barnes-Holmes Y, Stewart I, Luciano C. 2007. Experiential avoidance and aversive visual images: Response delays and event-related potentials on a simple matching task. Behav Res Ther 45:1379-1388. (Pubitemid 46590100)
13. Delis D, Kaplan E, Kraemer JH. 2001. Delis-Kaplan executive function system (D-KEFS). San Antonio, Texas, USA: The Psychological Corporation.
14. Fan J, McCandliss BD, Sommer T, Raz A and Posner MI. 2002. Testing the effi ciency and independence of attentional networks. J Cogn Neurosci 14:340-347. (Pubitemid 34267537)
15. Faraone SV, Biederman J, Doyle A, Murray K, Petty C, Adamson JJ, et al. 2006. Neuropsychological studies of late onset and subthreshold diagnoses of adult attention-defi cit/hyperactivity disorder. Biol Psychiatry 60:1081-1087. (Pubitemid 44754858)
16. Faraone SV, Biederman J, Spencer T, Wilens T, Seidman LJ, Mick E, et al. 2000. Attention defi cit hyperactivity disorder in adults: an overview. Biol Psychiatry 48:9-20.
17. Fayyad J, De Graaf R, Kessler R, Alonso J, Angermeyer M, Demyttenaere K, et al. 2007. Cross-national prevalence and correlates of adult attention-defi cit hyperactivity disorder. Br J Psychiatry 190:402-409. (Pubitemid 46706952)
18. Findling RL, McNamara NK, Stansbrey RJ, Maxhimer R, Periclou A, Mann A, et al. 2007. A pilot evaluation of the safety, tolerability, pharmacokinetics, and effectiveness of memantine in pediatric patients with attention-defi cit/hyperactivity disorder combined type. J Child Adolesc Psychopharmacol 17:19-33. (Pubitemid 46452079)
19. First M, Spitzer R, Gibbon M, Williams J. 1997. Structured Clinical Interview for DSM-IV Axis I Disorders. Washington, DC: American Psychiatric Press.
20. Jensen V, Rinholm JE, Johansen TJ, Medin T, Storm-Mathisen J, Sagvolden T, et al. 2009. N-Methyl-D-aspartate receptor subunit dysfunction at hippocampal glutamatergic synapses in an animal model of attention-defi cit/hyperactivity disorder. Neuroscience 158:353-364.
21. Kessler RC, Adler L, Barkley R, Biederman J, Conners CK, Demler O, et al. 2006. The prevalence and correlates of adult ADHD in the United States: Results from the National Comorbidity Survey Replication. Am J Psychiatry 163:716-7 23. (Pubitemid 44464584)
22. Kotecha SA, Oak JN, Jackson MF, Perez Y, Orser BA, Van Tol HH, et al. 2002. A D2 class dopamine receptor transactivates a receptor tyrosine kinase to inhibit NMDA receptor transmission. Neuron 35:1111-1122. (Pubitemid 35279538)
23. Logan GD. 1994. A users guide to the stop signal paradigm. In: Inhibitory processes in attention, memory and language. San Francisco, CA: Academic Press. p. 189-239.
24. Michelson D, Adler L, Spencer T, Reimherr FW, West SA, Allen AJ, et al. 2003. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 53: 112-120. (Pubitemid 36126473)
25. Murphy K, Barkley RA. 1996. Attention defi cit hyperactivity disorder adults: Comorbidities and adaptive impairments. Compr Psychiatry 37:393-401. (Pubitemid 26383062)
26. Orvaschel H. 1994. Schedule for Affective Disorder and Schizophrenia for School-Age Children Epidemiologic Version. Ft. Lauderdale, FL: Nova Southeastern University, Center for Psychological Studies.
27. Plosker GL, Lyseng-Williamson KA. 2005. Memantine: a pharmacoeconomic review of its use in moderate-to-severe Alzheimer's disease. Pharmacoeconomics 23:193-206. (Pubitemid 40460658)
28. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. 2007. The worldwide prevalence of ADHD: A systematic review and metaregression analysis. Am J Psychiatry 164:942-948. (Pubitemid 46972911)
29. Rammsayer TH. 2006. Effects of pharmacologically induced changes in NMDA receptor activity on human timing and sensorimotor performance. Brain Res 1073-1074:407-416.
30. Roth R, Isquith P, Gioia G. 2005. BRIEF-A Behavior rating inventory of executive function-adult version, publication manual. Lutz: Psychological Assessment Resources, Inc.
31. Seidman LJ, Doyle AE, Fried R, Valera E, Crum K and Matthews L. 2004. Neuropsychological function in adults with attentiondefi cit/hyperactivity disorder. Psychiatr Clin North Am 27: 261-282. (Pubitemid 38452767)
32. Smith GS, Schloesser R, Brodie JD, Dewey SL, Logan J, Vitkun SA, et al. 1998. Glutamate modulation of dopamine measured in vivo with positron emission tomography (PET) and 11Craclopride in normal human subjects. Neuropsychopharmacology 18:18-25. (Pubitemid 28116370)
33. Turic D, Langley K, Mills S, Stephens M, Lawson D, Govan C, et al. 2004. Follow-up of genetic linkage fi ndings on chromosome 16p13: Evidence of association of N-methyl-D aspartate glutamate receptor 2A gene polymorphism with ADHD. Mol Psychiatry 9:169-173. (Pubitemid 38299530)
34. Verma A, Moghaddam B. 1996. NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: Modulation by dopamine. J Neurosci 16:373-379. (Pubitemid 26010723)
35. Wanchoo SJ, Swann AC, Dafny N. 2009. Descending glutamatergic pathways of PFC are involved in acute and chronic action of methylphenidate. Brain Res 1301:68-79.
36. Warton FL, Howells FM, Russell VA. 2009. Increased glutamatestimulated release of dopamine in substantia nigra of a rat model for attention-defi cit/hyperactivity disorder-lack of effect of methylphenidate. Metab Brain Dis 24:599-613.
37. Wechsler D. 1999. Wechsler Abbreviated Scale of Intelligence (WASI). San Antonio, TX: The Psychological Corporation.
38. Wechsler D. 1997. Wechsler Adult Intelligence Scale III [manual]. San Antonio, TX: The Psychological Corporation.
39. Wenk GL, Parsons CG, Danysz W. 2006. Potential role of N-methyl-D-aspartate receptors as executors of neurodegeneration resulting from diverse insults: Focus on memantine. Behav Pharmacol 17:411-424. (Pubitemid 44325803)
40. Wilkinson GS. 1993. WRAT3 Wide Range Achievement Test: Administration Manual. Wilmington, DE: Wide Range, Inc.